This article summarized the latest R&D progress of Rimonabant, the Mechanism of Action for Rimonabant, and the drug target R&D trends for Rimonabant.

On 23 Oct 2023, the results from a phase II trial of endostar in patients with locally advanced squamous cell carcinoma of esophagus were reported at the ESMO Congress.

The FDA greenlights Lilly's Zepbound™ (tirzepatide) - a potent, new choice for managing persistent weight issues, including obesity or overweight cases with health issues connected to weight.

BRD4 inhibitors, developed using computer-assisted drug design, are viewed as potential therapies for various diseases due to BRD4's involvement in gene expression, chromatin remodeling, cell cycle, and cancer.

This article summarized the latest R&D progress of Rivastigmine Tartrate, the Mechanism of Action for Rivastigmine Tartrate, and the drug target R&D trends for Rivastigmine Tartrate.

On October 20, 2023, “Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts) ”was reported at the ESMO Congress.

Amgen has revealed fresh information from the Phase 2 trial of dazodalibep, an experimental drug aimed to treat Sjögren's.

BRAF mutation is one of the significant therapeutic targets for various solid tumors, with BRAF inhibitors representing a major form of targeted combination therapy for BRAF mutation-positive solid tumors.

This article summarized the latest R&D progress of Sacituzumab govitecan-hziy, the Mechanism of Action for Sacituzumab govitecan-hziy, and the drug target R&D trends for Sacituzumab govitecan-hziy.

[177Lu]Lu-PSMA-617 extends survival in mCRPC patients previously treated with ARPI, but its impact without prior taxane treatment was unclear until revealed at the ESCO Congress.

FluoGuide A/S, a precision oncology surgery leader, shared initial results from the phase IIa trial of its leading product, FG001, for head and neck cancer surgeries, at the International Academy of Oral Oncology 2023 conference in South Korea. The study validated the product's efficacy and safety.

β-Inhibitors can inhibit the activity of β-lactamase inhibitors produced by drug-resistant bacteria. They are typically used in combination with β-lactam antibiotics to protect the β-lactam antibiotics from hydrolysis, thereby inhibiting enzyme-resistant bacteria.